CRL Maintained by Evercore ISI Group -- Price Target Raised to $
Evercore ISI Group maintained its 'Outperform' rating for Charles River Laboratories (CRL) and raised its price target from $300 to $320. The company's stock is currently trading at $279.37, which is 43.8% above its GF Value™ of $194.25, indicating potential overvaluation. CRL has a GF Score™ of 69/100, with strengths in profitability and momentum, but weaknesses in valuation. Insider selling totaled $42.6 million over the last three months.
How this was made
The 30-second read
Why it matters
Analyst rating upgrade may boost demand for the stock, but valuation concerns and insider selling temper expectations.
Market read
The rating upgrade provides a new data point for traders monitoring mid‑cap biotech stocks.
What to watch
Recent insider selling of $42.6 M and a negative EPS of $‑4.85 suggest downside risk.
Background
Charles River Laboratories provides drug discovery services and animal testing models; its market cap is about $13.3 B.
Ticker impact
Evercore ISI Group maintained an Outperform rating and raised the price target for Charles River Laboratories to $320, indicating a fresh analyst upgrade.
Potential modest upside toward the new $320 target over the next few weeks.
Analyst upgrades historically move mid‑cap stocks; however, the stock is already considered overvalued, limiting upside.
Market effects
May influence sentiment toward the broader biotech and contract research services sector.
Limited to U.S. markets where CRL trades.
Low; impact confined to investors tracking contract research firms.
Counterpoint
The stock appears significantly overvalued; the price target raise could be premature.
Key entities
- Analyst FirmEvercore ISI Group
Maintained Outperform rating and raised price target.
- CompanyCharles River Laboratories
Subject of the rating change.